Pharma mergers and acquisitions stay subdued while China’s industry influence grows

The pharmaceutical industry is expected to see significant growth over the next decade, with global prescription drug sales projected to exceed $1.75 trillion by 2030. Despite this positive outlook, the industry is facing historic changes that could impact its future trajectory.

Reports suggest that demand for prescription drugs globally remains high, which serves as a driving force behind the industry’s growth amidst various challenges. With an estimated annual compound growth rate of over 7% in the coming years, the industry is expected to thrive. Specific areas like obesity drugs and GLP-1s are anticipated to experience significant growth, with an estimated 20% yearly increase between 2024 and 2030.

However, industry experts are cautious about the potential uncertainties and disruptions that could affect the industry in the near future. Factors such as policy changes, regulatory shifts at the Food and Drug Administration, and funding cuts at the National Institutes of Health are contributing to a climate of unpredictability. These challenges are hindering large dealmaking and initial public offerings (IPOs) in the sector, creating constraints that are impacting the industry’s overall growth.

One significant trend reshaping the pharmaceutical landscape is the rise of China’s influence in the global market. As China increases its presence in pharmaceutical production, there has been a notable shift in the industry dynamics. Currently, China accounts for 40% of all licensing deals in 2025, a stark increase from 3% just five years ago. This transformation highlights China’s growing dominance in the pharmaceutical sector, as it is able to produce innovative molecules more efficiently and cost-effectively than the U.S.

This shift in power dynamics could have far-reaching consequences for Western biopharma companies. As China becomes a leading global player in pharmaceuticals, the pressure is on for Western companies to enhance their research and development efficiency to stay competitive. The adoption of artificial intelligence (AI) is expected to play a crucial role in driving domestic pharma productivity, although the full extent of its impact remains to be seen.

Looking to the future, questions remain about the implications of increased collaboration with China on investment patterns and the distribution of funds. The pharmaceutical landscape is evolving rapidly, presenting both opportunities and challenges for industry players as they navigate this period of transformation.

Overall, while the pharmaceutical industry remains on a growth trajectory, disruptive forces and shifting dynamics are reshaping its landscape. As stakeholders adapt to emerging trends and navigate uncertainties, strategic decision-making and innovation will be critical to ensuring long-term success in this evolving environment.